8-K: ZimVie Reports Mixed Q4 and Full Year 2023 Results, Focuses on Dental Business Post-Spine Sale

ZimVie's fourth quarter and full year 2023 results show a mixed performance with a focus on the upcoming sale of its spine business and a transition to a pure-play dental company.

Summary

• ZimVie reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company is transitioning to a pure-play dental company following the planned sale of its spine business for $375 million, expected to close in the first half of 2024.
• For continuing operations, which includes the dental business, fourth quarter net sales were $113.1 million, a decrease of 2.4% on a reported basis and 3.6% on a constant currency basis compared to the same period in 2022.
• The net loss for continuing operations in Q4 2023 was $22.2 million, compared to a net loss of $15.4 million in Q4 2022.
• Adjusted EBITDA for continuing operations in Q4 2023 was $13.9 million, or 12.3% of net sales, an increase of 160 basis points from the fourth quarter 2022 margin of 10.7%.
• For discontinued operations, which includes the spine business, fourth quarter net sales were $100.5 million, a decrease of 10.6% on both a reported and constant currency basis compared to the same period in 2022.
• The net loss from discontinued operations was $312.7 million, which includes a $289.5 million write-down of the spine disposal group to fair value.
• Full year 2023 net sales for continuing operations were $457.2 million, a decrease of 0.5% on a reported basis and 0.6% on a constant currency basis compared to 2022.
• The full year net loss for continuing operations was $56.0 million, compared to a net loss of $46.9 million in 2022.
• Full year 2023 net sales for discontinued operations were $409.2 million, a decrease of 9.0% on a reported basis and 9.2% on a constant currency basis compared to 2022.
• The full year net loss from discontinued operations was $337.2 million, which includes a $289.5 million write-down of the spine disposal group to fair value.
• The company projects first quarter 2024 net sales for continuing operations to be between $115 million and $118 million, and for discontinued operations to be between $89 million and $91 million.
• ZimVie has raised its financial targets for the 12-month period post-spine sale, projecting net sales of $455 million or more, an adjusted EBITDA margin of 15% or more, and net debt of less than $200 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is making a strategic shift to focus on the dental business, the current financial results are mixed with significant losses in the discontinued operations and a decrease in sales. The future outlook is positive, but there are risks associated with the transition.

Positives

• Adjusted EBITDA margin for continuing operations increased in the fourth quarter of 2023.
• The company is on track to complete the sale of its spine business in the first half of 2024.
• ZimVie is focusing on its dental business, which has a comprehensive and industry-leading portfolio.
• The company has raised its financial targets for the dental business post-spine sale.
• ZimVie is aiming for a leaner cost structure and optimized product manufacturing.

Negatives

• Net sales for both continuing and discontinued operations decreased in the fourth quarter and full year of 2023.
• The company reported a significant net loss from discontinued operations due to a $289.5 million write-down of the spine disposal group.
• The full year net loss for continuing operations increased compared to the previous year.
• The company's net debt is currently around $421 million.

Risks

• There are uncertainties regarding the timing of the sale of the spine business and the risk that the transaction may not be completed.
• The announcement of the sale could affect the company's ability to retain key personnel and maintain relationships with customers and suppliers.
• Management's attention may be diverted from ongoing business operations due to the sale of the spine business.
• The company faces risks related to new product development, technological advances, and innovation.
• There are risks associated with shifts in product category or regional sales mix, supply and prices of raw materials, and pricing pressures from competitors.
• The company is subject to changes in governmental laws and regulations, including those related to the FDA and foreign government regulators.
• There are risks related to competition, healthcare reform measures, and reductions in reimbursement levels by third-party payors.
• The company is dependent on a limited number of suppliers for key raw materials and outsourced activities.
• There are risks related to breaches or failures of information technology systems, including cyberattacks.
• The company's ability to attract, retain, and develop highly skilled employees is a risk.
• There are risks associated with financing transactions undertaken in connection with the separation and additional indebtedness.
• The company faces risks related to product liability, intellectual property, and commercial litigation losses.
• Changes in general industry and market conditions, including economic conditions and currency exchange rate fluctuations, pose risks.
• The effects of the COVID-19 global pandemic and other adverse public health developments on the global economy and the company's business are a risk.

Future Outlook

ZimVie is focused on its dental business and expects to achieve significant growth and profitability improvements following the sale of its spine business. The company has raised its financial targets for the 12-month period post-spine sale, projecting increased net sales, adjusted EBITDA margin, and reduced net debt.

Management Comments

• We had significant accomplishments in 2023.
• We invested to further differentiate our portfolio which helped us make gains in the markets we serve, and we improved our operating efficiency through restructuring and cost reduction initiatives.
• We successfully executed an agreement to sell our spine business and transform ZimVie into a pure play dental company with a comprehensive and industry leading portfolio.
• We are optimistic about the future of ZimVie as a purely dental focused company with a strong capital structure.

Industry Context

The announcement reflects a strategic shift for ZimVie to focus on the dental market, which is seen as a high-growth area. The divestiture of the spine business aligns with a trend of companies streamlining their portfolios to concentrate on core competencies. The dental market is characterized by a significant unmet need for tooth replacement, which presents a long-term growth opportunity for ZimVie.

Comparison to Industry Standards

• ZimVie's performance is being assessed against the backdrop of the broader medical device industry, where companies are increasingly focusing on specific high-growth segments.
• The dental implant market, where ZimVie is now concentrating, is competitive, with key players like Straumann, Danaher (Envista), and Dentsply Sirona.
• ZimVie's projected 15%+ adjusted EBITDA margin post-spine sale is a key metric to watch, as it will be compared to the profitability of its peers in the dental sector.
• The company's ability to achieve its target of 20%+ adjusted EBITDA margin and 80%+ free cash flow conversion in the long term will be critical for its success as a pure-play dental company.
• The sale of the spine business for $375 million is a significant transaction, and its impact on ZimVie's financial position and future growth will be closely monitored by investors.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the strategic shift to a pure-play dental company.
• Employees may be affected by the restructuring and the sale of the spine business.
• Customers will see a change in the company's focus and product offerings.
• Suppliers may be impacted by the changes in the company's operations.
• Creditors will be affected by the company's financial performance and debt levels.

Next Steps

• ZimVie will complete the sale of its spine business in the first half of 2024.
• The company will focus on growing its dental business and improving its financial performance.
• ZimVie will work towards achieving its financial targets for the 12-month period post-spine sale.
• The company will continue to innovate and expand its portfolio in the dental market.

Key Dates

Keywords

dental, spine, financial results, net sales, EBITDA, discontinued operations, continuing operations, restructuring, divestiture, implants, biomaterials, digital dentistry